Moreover, a mathematical model simulating the effect of combining RT with ICIs, based on trial data of HCC patients treated with durvalumab (anti-PD-L1), demonstrated that maximal response is observed when RT and ICIs are given concurrently and that there is a significant reduction in response when the timing between the end of RT and the start of ICIs increases [105]. This evidence concerns the gene CD274 and hepatocellular carcinoma.